India, March 11 -- Ascletis Pharma Inc. (ASCLF.PK) announced promising pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies conducted in Australia. Part I of the study focused on healthy subjects with elevated low-density lipoprotein cholesterol (LDL-C), while Part II involved patients with obesity.
ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single subcutaneous injection studies in healthy subjects with elevated LDL-C and patients with obesity, supporting once-monthly to once-bimonthly administration. Furthermore, ASC47 subcutaneous injection demonstrated d...